NEW YORK and SYDNEY, Oct. 3, 2016 /PRNewswire/ -- EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, announced that Jennifer MacDiarmid, Ph.D., joint-CEO and co-founder, has been named a recipient of The Australian Financial Review and Westpac 100 Women of Influence Awards for 2016. Dr. MacDiarmid was recognized in the Innovation category for her contribution to cancer research.
Dr. MacDiarmid commented, "As a co-founder of EnGeneIC, my focus has been on building a biotechnology company to develop groundbreaking technologies designed to combat cancer and save lives. However, I also recognize that my accomplishments along with those of other pioneering women in the biotechnology field are paving the way for a new generation of women scientists and executives to have a positive influence in Australia and around the world. I am honored to be named as one of the 100 Women of Influence for 2016 and would like to thank the judges, The Australian Financial Review, Westpac, my supportive and resilient husband, Ian, and especially, my co-founder and joint-CEO Himanshu Brahmbhatt, together with our EnGeneIC team."
Dr. Brahmbhatt stated, "Jennifer is an inspirational partner who constantly provides motivation for the EnGeneIC team, an extremely diverse group dedicated towards finding better treatment options against cancer. Based on the clinical and pre-clinical results, we believe that our EDV nanocell platform represents a promising new approach in difficult-to-treat cancers. Despite her heavy workload, Jennifer has also been extremely active in mentoring young scientists through the scholarship program that forms the key aim of our charity, the EnGeneIC Cancer Research Foundation (ECRF)."
In its fifth year, the 100 Women of Influence Awards celebrate outstanding women from a wide variety of sectors across Australia. There are 10 categories: Board/Management, Public Policy, Diversity, Business Enterprise, Young Leader, Global, Local/Regional, Innovation, Arts, Culture and Sport, and Social Enterprise/Not-for-profit. Award entrants were assessed by a panel of well-regarded judges and have been recognized based on their exceptional ability to demonstrate innovation, vision, leadership and action in their fields.
A gala awards evening celebrating these inspirational women and the resounding impact they have had within their chosen field will be held at Sydney Town Hall on Thursday, October 27, 2016.
Ainslie van Onselen, Westpac's Director of Women's Markets, Diversity and Inclusion, remarked, "Influence is the power to make change, and women across Australia are using this power to transform the country and to make an impact abroad – and we saw this in the caliber of this year's nominees. It is an honor to be able to recognize and award the incredible work these women have made ongoing to our society. We know that women have the power and expertise to influence change. This year's Women of Influence winners, such as Jennifer MacDiarmid, are an example of how women are not waiting for change; they are backing themselves and acting now to make a real impact."
Joanne Gray, The Australian Financial Review BOSS Editor, said, "It's not just a senior job title that confers influence - the women chosen as winners this year have gone above and beyond their roles to create a positive legacy. We are thrilled to be recognizing this fresh cohort of extraordinary women."
Australian women were nominated for the 2016 Awards in recognition of their outstanding work in their respective fields and ability to inspire those around them. The 2016 winners join an alumnus of 500 of Australia's most inspiring women.
EnGeneIC is a clinical stage biopharmaceutical company focused on developing its proprietary bacterially-derived EDV™ nanocells as a powerful nanoparticle drug, siRNA, or miRNA delivery platform designed to directly target and effectively kill tumor cells with minimal toxicity, while simultaneously stimulating the immune system's natural anti-tumor response. Intravenously injected EDV™ nanocells exit the leaky vascular system only found within tumors and attach to cancer cells via a specially designed, targeted bi-specific antibody. Once attached, the nanocell is able to enter the tumor cell and deliver a drug, siRNA, or miRNA payload at high concentrations, intracellularly. The EDV™ nanocell platform has shown promising results in early clinical studies and EnGeneIC is currently planning to commence further clinical trials in several cancer indications in Australia and USA.